Can DRL’s new product launches offset the slowdown in Revlimid sales ?
Dr Reddy's Laboratories saw a high single-digit revenue increase in Q3, driven by India, emerging, and European markets, despite a muted US business. The company launched 24 new products, with a pipeline of 100 products expected to offset slowing Revlimid sales. Analysts remain cautious, with (...)
Site référencé: The Economic Times
The Economic Times
How are Indian IT giants navigating AI demands and tariff uncertainty ?
17/10/2025
Indian stock indices surge 1% as investors anticipate US-India trade truce
17/10/2025
Digital public platforms should be accessible to entire world : RBI Guv Sanjay Malhotra
16/10/2025
IPO-bound Groww launches commodities trading services on platform
16/10/2025
LTIMindtree Q2 Results : Cons PAT jumps 12% YoY to Rs 1,401 crore, revenue up 10%
16/10/2025
Vijay Kedia's portfolio multibagger surges 20%, extends rally to 30% in three sessions
16/10/2025
